[Old and new antibiotics for therapy of multidrug resistant bacteria].
The lack of new antibiotics for multidrug-resistant bacteria is a matter of concern in microorganisms such as Pseudomonas aeruginosa, ESBL- and carbapenemase-producing Enterobacteriaceae, Acinetobacter baumannii, methicillin-resistant Staphylococcous aureus and vancomycin-resistant Enterococcus faecium. This situation has conditioned the reuse of "old" antibiotics (colistin, fosfomycin), the use of more recent antibiotics with new indications or dosage regimens (tigecycline, meropenem) and the introduction of "new" antibiotics (β-lactams, lipoglycopeptides, oxazolidinones) that are the subject of this review.
Vicente Pintado, Servicio de Enfermedades Infecciosas. Hospital Ramón y Cajal. Madrid, Spain. vicente.pintado@salud.madrid.org.
V
V
Pintado
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology*; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects*; D006801:Humans; D047090:beta-Lactams / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D047090:beta-Lactams